[What significance to genotype changes have in diagnosis of malignant hyperthermia?].
Malignant hyperthermia (MH) is a potentially fatal, inherited pharmacogenetic disorder characterised by a dysfunction of the intracellular calcium regulation. Linkage to DNA markers from the chromosome 19q12-13.2 region and the MHS-phenotype (MH susceptible) has been shown in about 50% of families with a history of MH. The ryanodine receptor gene encoding the human skeletal muscle ryanodine receptor has been localised to the chromosome 19q13.1-13.2 region. The ryanodine receptor, which is an intracellular calcium release channel, has been proposed to be one of the candidate structures for the MH defect. At present, eight different single point mutations have been identified in the human skeletal muscle ryanodine receptor gene in families with disposition to MH. The incidence of the various mutations has been reported as 2-10% each. A combination of different mutations within one pedigree has not been demonstrated. A few years ago, linkage of the MHS-phenotype to DNA markers from the chromosome 17q11.2-24 region was published by an American group. However, this observation has not been confirmed in any of the several European families susceptible to MH. Genes encoding for subunits of the dihydropyridine receptor and the sodium channel of the human skeletal muscle have been found to be located in the chromosome 17q11.2-24 region which, in fact, could be additional candidates for the MH defect. The dihydropyridine receptor is linked to the ryanodine receptor and involved in the calcium regulation of skeletal muscle. Very recent studies have shown linkage to DNA markers from chromosome 7q- and chromosome 3q13.1 regions and the MHS phenotype in two distinct families with history of MH. However, the relevance of this observation is so far unknown. At present, unambiguous preoperative screening of MH disposition based on molecular genetic characteristics is not available because of the enormous heterogeneity of the human MH syndrome. Thus, the halothane-caffeine in-vitro contracture test according to the standard protocol of the "European MH Group" must be performed in order to discover MH susceptibility.
Steinfath
M
M
Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf.
Scholz
J
J
Singh
S
S
Wappler
F
F
D015220:Calcium Channels / Q000235:genetics; D002869:Chromosome Aberrations / Q000235:genetics*; D002874:Chromosome Mapping; D002886:Chromosomes, Human, Pair 17; D002888:Chromosomes, Human, Pair 19; D002893:Chromosomes, Human, Pair 3; D002897:Chromosomes, Human, Pair 7; D005819:Genetic Markers / Q000235:genetics; D005838:Genotype; D006801:Humans; D008305:Malignant Hyperthermia / Q000175:diagnosis / Q000235:genetics*; D009124:Muscle Proteins / Q000235:genetics; D010641:Phenotype; D012307:Risk Factors; D019837:Ryanodine Receptor Calcium Release Channel
D015220:Calcium Channels; D005819:Genetic Markers; D009124:Muscle Proteins; D019837:Ryanodine Receptor Calcium Release Channel
Welche Bedeutung haben Genotypveränderungen in der Diagnostik der malignen Hyperthermie?